FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914243257> ?p ?o ?g. }

• W2914243257 endingPage "722" @default.
• W2914243257 startingPage "714" @default.
• W2914243257 abstract "PURPOSE Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake values corrected for lean body mass (SULmax) on [ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography would predict pathologic complete response (pCR) to neoadjuvant pertuzumab and trastuzumab (PT). PATIENTS AND METHODS Patients with stage II/III, estrogen receptor–negative, HER2-positive breast cancer received four cycles of neoadjuvant PT. [ 18 F]Fluorodeoxyglucose positron emission tomography/computed tomography was performed at baseline and 15 days after PT initiation (C1D15). Eighty evaluable patients were required to test the null hypothesis that the area under the curve of percentage of change in SULmax by C1D15 predicting pCR is less than or equal to 0.65, with a one-sided type I error rate of 10%. RESULTS Eighty-eight women were enrolled (83 evaluable), and 85% (75 of 88) completed all four cycles of PT. pCR after PT alone was 34%. Receiver operating characteristic analysis yielded an area under the curve of 0.76 (90% CI, 0.67 to 0.85), which rejected the null hypothesis. Between patients who obtained pCR versus not, a significant difference in median percent reduction in SULmax by C1D15 was observed (63.8% v 33.5%; P < .001), an SULmax reduction greater than or equal to 40% was more prevalent (86% v 46%; P < .001; negative predictive value, 88%; positive predictive value, 49%), and a significant difference in median C1D15 SULmax (1.6 v 3.9; P < .001) and higher proportion of C1D15 SULmax less than or equal to 3 (93% v 38%; P < .001; negative predictive value, 94%; positive predictive value, 55%) were observed. CONCLUSION Early changes in SULmax predict response to four cycles of PT in estrogen receptor–negative, HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate a more tailored approach to therapy in this setting." @default.
• W2914243257 created "2019-02-21" @default.
• W2914243257 creator A5003110303 @default.
• W2914243257 creator A5004542056 @default.
• W2914243257 creator A5022075109 @default.
• W2914243257 creator A5024804370 @default.
• W2914243257 creator A5026024346 @default.
• W2914243257 creator A5027858713 @default.
• W2914243257 creator A5032785430 @default.
• W2914243257 creator A5033364146 @default.
• W2914243257 creator A5034353648 @default.
• W2914243257 creator A5041082382 @default.
• W2914243257 creator A5046693232 @default.
• W2914243257 creator A5049699694 @default.
• W2914243257 creator A5052268581 @default.
• W2914243257 creator A5053390874 @default.
• W2914243257 creator A5056530735 @default.
• W2914243257 creator A5063423721 @default.
• W2914243257 creator A5068780043 @default.
• W2914243257 creator A5070245248 @default.
• W2914243257 creator A5072850149 @default.
• W2914243257 creator A5075889627 @default.
• W2914243257 creator A5080832682 @default.
• W2914243257 creator A5084422985 @default.
• W2914243257 creator A5091723009 @default.
• W2914243257 date "2019-03-20" @default.
• W2914243257 modified "2023-09-26" @default.
• W2914243257 title "TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer" @default.
• W2914243257 cites W1985656391 @default.
• W2914243257 cites W2001268229 @default.
• W2914243257 cites W2078142430 @default.
• W2914243257 cites W2095633632 @default.
• W2914243257 cites W2095861620 @default.
• W2914243257 cites W2101873015 @default.
• W2914243257 cites W2101979288 @default.
• W2914243257 cites W2114428747 @default.
• W2914243257 cites W2123591186 @default.
• W2914243257 cites W2137853125 @default.
• W2914243257 cites W2139248078 @default.
• W2914243257 cites W2147299492 @default.
• W2914243257 cites W2152575748 @default.
• W2914243257 cites W2155263737 @default.
• W2914243257 cites W2166199281 @default.
• W2914243257 cites W2198899045 @default.
• W2914243257 cites W2225412566 @default.
• W2914243257 cites W2316247073 @default.
• W2914243257 cites W2320829886 @default.
• W2914243257 cites W2328176404 @default.
• W2914243257 cites W2591481727 @default.
• W2914243257 cites W2764265362 @default.
• W2914243257 cites W2767814595 @default.
• W2914243257 cites W2795193052 @default.
• W2914243257 doi "https://doi.org/10.1200/jco.2018.78.7986" @default.
• W2914243257 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6424139" @default.
• W2914243257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30721110" @default.
• W2914243257 hasPublicationYear "2019" @default.
• W2914243257 type Work @default.
• W2914243257 sameAs 2914243257 @default.
• W2914243257 citedByCount "32" @default.
• W2914243257 countsByYear W29142432572019 @default.
• W2914243257 countsByYear W29142432572020 @default.
• W2914243257 countsByYear W29142432572021 @default.
• W2914243257 countsByYear W29142432572022 @default.
• W2914243257 crossrefType "journal-article" @default.
• W2914243257 hasAuthorship W2914243257A5003110303 @default.
• W2914243257 hasAuthorship W2914243257A5004542056 @default.
• W2914243257 hasAuthorship W2914243257A5022075109 @default.
• W2914243257 hasAuthorship W2914243257A5024804370 @default.
• W2914243257 hasAuthorship W2914243257A5026024346 @default.
• W2914243257 hasAuthorship W2914243257A5027858713 @default.
• W2914243257 hasAuthorship W2914243257A5032785430 @default.
• W2914243257 hasAuthorship W2914243257A5033364146 @default.
• W2914243257 hasAuthorship W2914243257A5034353648 @default.
• W2914243257 hasAuthorship W2914243257A5041082382 @default.
• W2914243257 hasAuthorship W2914243257A5046693232 @default.
• W2914243257 hasAuthorship W2914243257A5049699694 @default.
• W2914243257 hasAuthorship W2914243257A5052268581 @default.
• W2914243257 hasAuthorship W2914243257A5053390874 @default.
• W2914243257 hasAuthorship W2914243257A5056530735 @default.
• W2914243257 hasAuthorship W2914243257A5063423721 @default.
• W2914243257 hasAuthorship W2914243257A5068780043 @default.
• W2914243257 hasAuthorship W2914243257A5070245248 @default.
• W2914243257 hasAuthorship W2914243257A5072850149 @default.
• W2914243257 hasAuthorship W2914243257A5075889627 @default.
• W2914243257 hasAuthorship W2914243257A5080832682 @default.
• W2914243257 hasAuthorship W2914243257A5084422985 @default.
• W2914243257 hasAuthorship W2914243257A5091723009 @default.
• W2914243257 hasBestOaLocation W29142432572 @default.
• W2914243257 hasConcept C121608353 @default.
• W2914243257 hasConcept C126322002 @default.
• W2914243257 hasConcept C143998085 @default.
• W2914243257 hasConcept C199374082 @default.
• W2914243257 hasConcept C2775842073 @default.
• W2914243257 hasConcept C2778292576 @default.
• W2914243257 hasConcept C2779786085 @default.
• W2914243257 hasConcept C2781164504 @default.
• W2914243257 hasConcept C2908728163 @default.
• W2914243257 hasConcept C2989005 @default.

• next